Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adynovate
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Adynovate (rurioctocog alfa pegol) is a PEGylated recombinant antihemophilic factor (Factor VIII) developed for the treatment of hemophilia A. It is based on octocog alfa, a full-length recombinant Factor VIII, but utilizes proprietary PEGylation technology to extend the circulating half-life of the protein. This modification allows for a less frequent prophylactic dosing schedule (typically twice weekly) compared to non-modified Factor VIII products while maintaining efficacy in preventing and controlling bleeding episodes. Originally developed by Baxalta (which was acquired by Shire, and subsequently by Takeda), Adynovate is indicated for use in both adults and children with hemophilia A for on-demand treatment, perioperative management, and routine prophylaxis. It functions as a replacement therapy, restoring the intrinsic pathway of the coagulation cascade by acting as a cofactor for factor IXa in the activation of factor X.
- Brand names
- AdynovateAdynovi
- Other names
- rurioctocog alfa pegolPEGylated recombinant factor VIIIPEGylated antihemophilic factor (recombinant)
02
Targets
F8 (Coagulation Factor VIIIa)LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on Adynovate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adynovate.